GlassScriptPhysician profile
John Thomas Zimmermann
NPI 1740221225
$6,979.25
in general payments reported to CMS, 2019-2025
45 companies · $1,876 in 2025
The $1,876 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $97.38 · 2020: $335 · 2021: $363 · 2022: $388 · 2023: $2,232 · 2024: $1,688 · 2025: $1,876.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,777 · Education: $18.18.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,777.48 |
| Education | $18.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $790.86 | 2019-2025 | Imfinzi, Tagrisso, Calquence |
| Myriad Genetic Laboratories, INC. | $666.86 | 2023-2024 | Myrisk |
| Emd Serono, INC. | $595.66 | 2020-2024 | Bavencio |
| Janssen Biotech, INC. | $535.95 | 2019-2025 | Rybrevant, Carvykti, Akeega |
| Merck Sharp & Dohme LLC | $443.23 | 2020-2025 | Keytruda, Lynparza, Welireg |
| Exelixis INC. | $432.81 | 2019-2025 | Cabometyx |
| E.R. Squibb & Sons, L.L.C. | $411.47 | 2021-2024 | Reblozyl, Opdivo, Opdualag |
| Astellas Pharma US INC | $282.15 | 2023-2025 | Padcev, Vyloy |
| Regeneron Healthcare Solutions, INC. | $266.41 | 2023-2025 | Libtayo |
| Jazz Pharmaceuticals INC. | $250.00 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $193.39 | 2023-2025 | Orgovyx |
| Novartis Pharmaceuticals Corporation | $188.96 | 2019-2025 | |
| Daiichi Sankyo INC. | $165.77 | 2020-2025 | Injectafer, Enhertu |
| Glaxosmithkline, LLC. | $163.40 | 2022-2024 | Ojjaara |
| Cti Biopharma Corp. | $132.35 | 2023 | Vonjo |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Zimmermann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.